Germany supply disruption extends beyond Q1
Third-party supplier regulatory issues affecting 75% of German business; management cannot predict resolution but expects impact for at least a couple of quarters, capping growth at low single digits.
TORNTPHARM / Q1-FY26 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
U.S. business remains loss-making
Despite improved facility performance and contract wins, U.S. operations continue to post losses; management expects losses to decline quarter-on-quarter but profitability remains distant.
Brazil currency volatility distorts reported growth
Brazilian real depreciated ~15% last fiscal year and has since appreciated 10%, leaving a residual 5% currency headwind between constant currency and INR-reported growth for the quarter.
MR productivity questioned amid expansion costs
Analyst raised concerns about 1,000 MR additions over one year while growth rates haven't proportionally increased; management responded that MR additions take 12-18 months to show impact and emphasized 2-year horizon for evaluating expansion ROI.